For people facing aggressive bladder cancer that no longer responds to standard treatment, options have often been grim—either undergo life-changing surgery to remove the bladder or try less effective ...
There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report. An experimental new drug with the unwieldy name of cretostimogene ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results